Key Details
Price
$3.27PE Ratio
13.63Annual ROE
-4.78%Beta
-0.11Events Calendar
Next earnings date:
May 08, 2025Recent quarterly earnings:
Nov 08, 2024Recent annual earnings:
Mar 15, 2018Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring.
Toronto, Ontario--(Newsfile Corp. - November 6, 2024) - Consistent with its strategy to become a leading North American vertically integrated lithium producer, Avalon Advanced Materials Inc. (TSX: AVL) (OTCQB: AVLNF) ("Avalon" or the "Company"), is pleased to announce it has signed a memorandum of understanding with Qualcomm Technologies Inc. (the "MOU") on a strategic collaboration focused on Avalon's Thunder Bay lithium processing facility, advancing cutting-edge digital solutions that enhance operational efficiency and optimize data management. Under the MOU, Avalon intends to leverage Qualcomm Technologies' Industrial & Edge technologies to create a robust digital infrastructure to support mining activities across Avalon's operations.
FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with an exclusivity period of 120 days (the “Exclusivity Period”), during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the proposed strategic collaboration.
Toronto, Ontario--(Newsfile Corp. - September 17, 2024) - Avalon Advanced Materials Inc. (TSX: AVL) (OTCQB: AVLNF) ("Avalon" or the "Company") is pleased to share the release of a new video rendering showcasing the design and layout of the proposed processing facility at the Lake Superior Lithium Project in Thunder Bay, Ontario (the "Project"). Cannot view this video?
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Avalon Advanced Materials Inc. (TSX: AVL) (OTCQB: AVLNF) ("Avalon" or the "Company"), in conjunction with its Joint-Venture ("JV") partner SCR-Sibelco NV ("Sibelco"), is delighted to announce the commencement of an upcoming mineral resource update for the Separation Rapids Project in Kenora, Ontario. Managed by the Joint Venture Company Separation Rapids Ltd.
Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that the booth at the event in Austin “attracted a diverse group of potential clients and partners, including doctors, disease management companies, health and keto coaches, consumers, keto product manufacturers, and service providers interested in establishing a marketplace on our app and device.
Toronto, Ontario--(Newsfile Corp. - May 27, 2024) - Avalon Advanced Materials Inc. (TSX: AVL) (OTCQB: AVLNF) ("Avalon" or the "Company") is pleased to announce the results of an order of magnitude site infrastructure valuation report prepared by AFRY Canada ("AFRY") for the site of Avalon's proposed lithium processing facility in Thunder Bay, Ontario. The report highlights that the replacement cost of the infrastructure at Avalon's Thunder Bay site, factoring in its current condition, is estimated to be $46 million.
FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).
FAQ
- What is the primary business of Avalon Holdings?
- What is the ticker symbol for Avalon Holdings?
- Does Avalon Holdings pay dividends?
- What sector is Avalon Holdings in?
- What industry is Avalon Holdings in?
- What country is Avalon Holdings based in?
- When did Avalon Holdings go public?
- Is Avalon Holdings in the S&P 500?
- Is Avalon Holdings in the NASDAQ 100?
- Is Avalon Holdings in the Dow Jones?
- When was Avalon Holdings's last earnings report?
- When does Avalon Holdings report earnings?